By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
No open-market selling at Immuneering Corp in the past year, which is unusual. Instead six insiders purchased about $270,000 worth of IMRX.
The largest purchase came from Schall Thomas J. (Director), about $101,000. Notably, at least one C-suite executive was among the buyers.
On the institutional side, 112 funds reported holding IMRX at the end of Q2 2026, and more funds bought than sold. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 5 of the last 7 full quarters.
Are insiders buying or selling IMRX stock?
In the last 12 months Immuneering Corp insiders made open-market purchases worth about $270,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in IMRX?
The most recent open-market insider trade in IMRX was filed on 2026-06-24.
How many institutions own IMRX?
112 investment managers reported holding IMRX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded IMRX?
No congressional trades in IMRX were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).